REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$784.85
−0.58%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$787.34
From 52W high−7.88%
Volume2.46M
Market cap$80.80B
P/E (TTM)18.7x
P/S (TTM)5.2x
Div yield0.47%
Key dataSep 18, 2026
Open
$787.34
From 52W high
−7.88%
Volume
2.46M
Market cap
$80.80B
ValuationView details →
P/E (Fwd)
13.0x
EV/EBITDA
13.0x
P/E (TTM)
18.7x
RSI (14)
47.6
MomentumView details →
1D Return
−0.58%
YTD Return
+1.60%
SummaryUpdated Jun 1, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company went public in 1991 and has evolved from a research-focused startup into one of the world's premier biotechnology companies. Regeneron discovers, develops, manufactures, and commercializes innovative medicines for serious diseases across multiple therapeutic areas including ophthalmology, immunology, oncology, and rare diseases. The company is known for its proprietary drug discovery platforms and has built a portfolio of blockbuster medicines that serve patients worldwide.
Similar companies
Latest newsMore news →
A securities class action was filed against Bloom Energy Corporation on behalf of shareholders who purchased securities between February 27, 2025 and July 8, 2026, alleging false and misleading statements about its scandium supply chain and China exposure.10d agoSueWallSt reminded shareholders of a September 29, 2026 lead plaintiff deadline in a securities class action against Pentwater Capital Management LP and its CEO over alleged manipulation of Avis Budget Group shares.10d ago